This protocol is judged by an institutional evaluation board, an independent team that evaluations any scientific trials involving human beings. If a review involves a Agenda I drug, when the board approves the protocol as ethical, the scientists should make an application for an investigational new drug (IND) variety through the FDA.When beneath t